Home  /  Resource Library  /  Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

ASH 2020: Results of a study examining nivolumab combined with brentuximab vedotin for consolidation following autologous stem cell transplant in patients with relapsed Hodgkin lymphoma.